Your browser doesn't support javascript.
loading
Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function.
Edwards-Hicks, Joy; Apostolova, Petya; Buescher, Joerg M; Maib, Hannes; Stanczak, Michal A; Corrado, Mauro; Klein Geltink, Ramon I; Maccari, Maria Elena; Villa, Matteo; Carrizo, Gustavo E; Sanin, David E; Baixauli, Francesc; Kelly, Beth; Curtis, Jonathan D; Haessler, Fabian; Patterson, Annette; Field, Cameron S; Caputa, George; Kyle, Ryan L; Soballa, Melanie; Cha, Minsun; Paul, Harry; Martin, Jacob; Grzes, Katarzyna M; Flachsmann, Lea; Mitterer, Michael; Zhao, Liang; Winkler, Frances; Rafei-Shamsabadi, David Ali; Meiss, Frank; Bengsch, Bertram; Zeiser, Robert; Puleston, Daniel J; O'Sullivan, David; Pearce, Edward J; Pearce, Erika L.
Afiliación
  • Edwards-Hicks J; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Apostolova P; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Buescher JM; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Maib H; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Stanczak MA; Division of Cell & Developmental Biology, School of Life Sciences, University of Dundee, Dundee, UK.
  • Corrado M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Klein Geltink RI; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Maccari ME; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Villa M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Carrizo GE; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Sanin DE; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Baixauli F; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Kelly B; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Curtis JD; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Haessler F; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Patterson A; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Field CS; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Caputa G; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Kyle RL; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Soballa M; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Cha M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Paul H; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Martin J; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Grzes KM; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Flachsmann L; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Mitterer M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Zhao L; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Winkler F; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Rafei-Shamsabadi DA; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Meiss F; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Bengsch B; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Zeiser R; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • Puleston DJ; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
  • O'Sullivan D; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Pearce EJ; Clinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Pearce EL; Faculty of Biology, University of Freiburg, Freiburg, Germany.
Nat Immunol ; 24(3): 516-530, 2023 03.
Article en En | MEDLINE | ID: mdl-36732424
ABSTRACT
How lipidome changes support CD8+ effector T (Teff) cell differentiation is not well understood. Here we show that, although naive T cells are rich in polyunsaturated phosphoinositides (PIPn with 3-4 double bonds), Teff cells have unique PIPn marked by saturated fatty acyl chains (0-2 double bonds). PIPn are precursors for second messengers. Polyunsaturated phosphatidylinositol bisphosphate (PIP2) exclusively supported signaling immediately upon T cell antigen receptor activation. In late Teff cells, activity of phospholipase C-γ1, the enzyme that cleaves PIP2 into downstream mediators, waned, and saturated PIPn became essential for sustained signaling. Saturated PIP was more rapidly converted to PIP2 with subsequent recruitment of phospholipase C-γ1, and loss of saturated PIPn impaired Teff cell fitness and function, even in cells with abundant polyunsaturated PIPn. Glucose was the substrate for de novo PIPn synthesis, and was rapidly utilized for saturated PIP2 generation. Thus, separate PIPn pools with distinct acyl chain compositions and metabolic dependencies drive important signaling events to initiate and then sustain effector function during CD8+ T cell differentiation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositoles / Fosfatos de Fosfatidilinositol Idioma: En Revista: Nat Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositoles / Fosfatos de Fosfatidilinositol Idioma: En Revista: Nat Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania